Cost-effectiveness analysis of sequential therapy of levofloxacin in the treatment of type Ⅲa prostatitis
10.13699/j.cnki.1001-6821.2015.11.036
- VernacularTitle:左氧氟沙星序贯治疗Ⅲa型前列腺炎的药物经济学分析
- Author:
Pei-Hong MIAO
1
;
Zhong-Jie HU
;
Jie CHENG
;
Zhen-Pei SHEN
;
Ming-An CHEN
Author Information
1. 武警浙江省总队医院
- Keywords:
levofloxacin;
type Ⅲa prostatitis;
sequential therapy;
pharmacoeconomics
- From:
The Chinese Journal of Clinical Pharmacology
2015;(11):1056-1059
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of sequential therapy of levofloxacin in the treatment of type Ⅲa prostatitis.Methods A total of 280 in-patients diagnosed typeⅢa prostatitis were enrolled in this study and randomized to administer with either levofloxacin 500 mg( n =140 ) for intravenous injection once daily for 28 days ( control group) or administered of levofloxacin injection 500 mg ( n=140 ) once daily for 7 days followed by oral levofloxacin 500 mg once daily for 21 days( sequential group).Clinical results and safety were observed and cost-effectiveness analysis was made after 4 -week therapeutic dura-tion.Results The clinical effective rates showed no significant difference between 2 groups ( P<0.05 ).But cost -effectiveness ratio and sensitivity analysis in sequential group was significantly lower than that in control group(P<0.05).The adverse drug reaction rates in con-trol group ( 15.71%) and sequential group ( 5.71%) showed significant difference between 2 groups ( P<0.05 ).Conclusion The sequential therapy with the antibiotic therapeutic of levofloxacin 500 mg once daily achieved similar clinical efficacy to mono-therapy and offered an eco-nomic superiority and less adverse reactions in the treatment of type Ⅲa prostatitis.
